If you will allow me to add on, I'll just add that it's an unbelievably pathetic deal IMHO. How they could not get double-digit royalties on what is not only a NCE, but what had to be considered a novel oncology target at that time (and still is as far as I know) is beyond me. It honestly makes me, rightly or wrongly, question everything about CRIS.
News 
Market Data 
Discover 
AI
